Head & Neck Cancers | Specialty

Cabozantinib Significantly Improves PFS in Previously Treated, Radioiodine-Refractory Differentiated Thyroid Cancer

December 21st 2020

December 21, 2020 - Cabozantinib was found to significantly improve progression-free survival compared with placebo in patients with dedifferentiated thyroid cancer who are refractory to radioiodine and have progressed following up to 2 prior VEGF-targeted treatments.

Thyrotropin Suppression as DTC Treatment Option

December 21st 2020

Role of Radioiodine Treatment in DTC

December 21st 2020

DTC: Histological Subtypes and Tumor Differentiation

December 14th 2020

Differentiated Thyroid Cancer: Increasing Incidence

December 14th 2020

FDA Approves Pralsetinib for RET+ Thyroid Cancers

December 1st 2020

December 1, 2020 - The FDA has approved pralsetinib for the treatment of select patients with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma

November 13th 2020

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

CD47 Blocker ALX148 Safe to Combine With Antibody Regimens, Chemotherapy in Gastric/GEJ and HNSCC

November 13th 2020

November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.

Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer

November 12th 2020

In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.

Dr. Saba Discusses Ongoing Trials in Head and Neck Cancer

November 12th 2020

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Ho Highlights the Latest Breakthroughs in Head, Neck, and Thyroid Cancers

November 11th 2020

Alan L. Ho, MD, PhD, highlights the great strides that have been made with head and neck cancer, including those with rarer diseases like thyroid cancer and salivary gland cancers, due to a greater understanding of disease biology and genomics.

AL101 Shows Promising Activity in Recurrent/Metastatic Adenoid Cystic Carcinoma With NOTCH Activating Mutations

November 4th 2020

The investigational small molecule, γ-secretase inhibitor AL101 monotherapy was found to elicit deep responses with a significant disease control rate in patients with recurrent or metastatic adenoid cystic carcinoma harboring NOTCH activating mutations.

Tipifarnib Shows Potential in HRAS-Mutant Head and Neck Cancers

November 4th 2020

Investigators are testing tipifarnib, a novel drug that inhibits a critical enzyme needed for HRAS activation, in patients with head and neck squamous cell carcinoma whose tumors harbor the mutation.

Axitinib Demonstrates Survival Benefit in Heavily Pretreated Unresectable Recurrent, or Metastatic Head and Neck Cancer

November 1st 2020

Heavily pretreated patients with unresectable recurrent or metastatic head and neck squamous cancer experienced an improvement in survival following treatment with axitinib.

Dr. Cohen on the Design on the SPEARHEAD-2 Trial in Head and Neck Cancer

October 29th 2020

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.

Dana-Farber Announces Center for Salivary and Rare Head and Neck Cancers

October 6th 2020

Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck.

Yale Cancer Center Awarded NIH SPORE for Head and Neck Cancer Research

October 1st 2020

Yale Cancer Center researchers were awarded a five-year, $11.7 million grant from the National Institutes of Health to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence.

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

September 20th 2020

Potent and durable clinical activity was shown with pralsetinib as treatment of patients with RET-mutant advanced medullary thyroid cancer, regardless of the line of therapy.

Updated Data Shows Xevinapant Significantly Improves OS in Locally Advanced Head and Neck Cancer

September 19th 2020

Three-year follow-up data for the phase 2 study of the first-in-class inhibitor of apoptosis protein antagonist, xevinapant, in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy reduced the risk of mortality by half compared with CRT alone in patients with locally advanced squamous cell carcinoma of the head and neck.

FDA Grants Priority Review to Pralsetinib for Metastatic RET+ Thyroid Cancers

September 5th 2020

The FDA has granted pralsetinib a priority review for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancer.